false
0001382574
0001382574
2026-05-18
2026-05-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 18, 2026
SCIENTURE
HOLDINGS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
| Delaware |
|
001-39199 |
|
46-3673928 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(I.R.S.
Employer
Identification
No.) |
20
Austin Blvd.
Commack,
NY 11725
(Address
of Principal Executive Offices)
(631)
670-6039
(Registrant’s
Telephone Number)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, par value $0.00001 per share |
|
SCNX |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On
May 18, 2026, Scienture Holdings, Inc. issued a press release announcing its financial results for the quarter ending March 31, 2026,
and other recent operational highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
The
information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward
Looking Statements
This
Current Report on Form 8-K contains certain statements that may be deemed to be “forward-looking statements” within the federal
securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are
not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange.
Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements
are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our
beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our management team’s
expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts
or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In
some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,”
“potential,” “predict,” “project,” “should,” or the negative of these terms or other
similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These
statements are based on our expectations and involve risks, uncertainties and other important factors that could cause our actual results
performance or achievements (or entities in which we have an interest), or industry results, to differ materially from future results,
performance or achievements expressed or implied by such forward-looking statements. Certain factors that could cause our actual future
results to differ materially from those discussed are noted in connection with such statements, but other unanticipated factors (including
those beyond our control) could arise. Certain risks regarding our forward-looking statements are discussed in our filings with the Securities
and Exchange Commission, including an extensive discussion of these risks in our Annual Report on Form 10-K for the year ending December
31, 2025, as amended, and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking
statements which reflect management’s view only as of the date of this Current Report on Form 8-K. We undertake no obligation to
publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events, conditions or circumstances.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release, dated May 18, 2026. |
| 104 |
|
Cover
Page Interactive Data File (embedded with the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SCIENTURE
HOLDINGS, INC. |
| |
|
|
| |
By:
|
/s/
Dr. Narasimhan Mani |
| |
|
Dr.
Narasimhan Mani |
| |
|
Co-Chief
Executive Officer |
| |
|
|
| Date:
May 22, 2026 |
|
|
Exhibit 99.1
SCIENTURE
Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
COMMACK,
NY, May 18, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for
existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through
the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business
update and reported financial results for the three months ended March 31, 2026.
Q1
2026 Financial Highlights Compared to Q1 2025:
| |
● |
Revenue
increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the
prior-year three-month period, representing an increase of approximately 449% year-over-year, reflecting incremental product orders
for ArbliTM in addition to the initial launch quantities ordered in the fourth quarter of 2025 |
| |
|
|
| |
● |
Gross
profit increased substantially to approximately $54 thousand, compared to approximately $673 in the prior-year three-month period,
representing an increase of approximately 7900% year-over-year, primarily as a result of the increase in ArbliTM product
orders |
| |
|
|
| |
● |
Gross
margin expanded to approximately 95.6% for the three months ended March 31, 2026, compared to approximately 6.6% in the prior-year
three-month period, also as a result of the increase in ArbliTM product orders |
Key
Operational Highlights in Q1 2026 and Subsequent Events:
| |
● |
United
States Patent and Trademark Office (USPTO) granted a third patent covering ArbliTM (losartan potassium) oral suspension,
further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041 |
| |
|
|
| |
● |
Received
an Orange Book-listable patent for REZENOPYTM (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone
HCl nasal spray for emergency opioid overdose treatment |
| |
|
|
| |
● |
Formalized
multiple commercial GPO agreements for REZENOPYTM, expanding access to over 5,000 healthcare institutions and reaching
approximately 60% of the U.S. institutional market, including first responders, EMS providers, and rehabilitation centers |
| |
|
|
| |
● |
Secured
$11.0 Million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of R&D pipeline |
Narasimhan
Mani, President and Co-CEO of Scienture, commented, “Our financial results for the quarter reflect the early progress of our commercialization
strategy, with revenue increasing approximately 449% year-over-year to $56 thousand, gross profit increasing approximately 7900% year-over-year
to $54 thousand, and gross margin expanding significantly to approximately 95.6%, compared to 6.6% in the prior-year period. The increase
in revenue and gross margin reflects incremental product orders received for ArbliTM during the first quarter of 2026, following
the significant initial launch quantity orders recorded in the fourth quarter of 2025.”
“During
the quarter, we experienced continued month-over-month growth in both prescriptions and units sold for ArbliTM. We are actively
working to enhance our promotional and commercial activities around the product to further increase physician awareness and market penetration.
We also continue to advance key commercial initiatives to support the planned launch of REZENOPYTM. Our sales force is scheduled
to begin operations on June 1, 2026, targeting key accounts and purchasing organizations, and we have also successfully secured key GPO
contracts that we believe will support broad commercial access and accelerate adoption following launch. Together, we believe the continued
commercialization of ArbliTM and the anticipated launch of REZENOPYTM will have a meaningful impact on our business
performance during the second half of 2026,” added Mani.
“In
addition, we recently secured $11.0 million through a non-dilutive debt financing transaction that we believe significantly strengthens
our capital position and provides important financial flexibility as we continue scaling our commercial operations,” stated Shankar
Hariharan, Executive Chairman and co-CEO of Scienture. “We believe this financing will serve as a catalyst to help position the
Company toward anticipated profitability in 2027, while also supporting the continued growth of our commercial product portfolio and
the progression of our R&D pipeline.”
Q1
2026 Financial Summary
Revenue
for the year three months ended March 31, 2026 increased 449% to $56 thousand, compared to $10 thousand in the prior year period, driven
by the continued ramp of wholesale distribution sales of SCN-102 (ArbliTM) following its commercial launch. Gross profit increased
to approximately $54 thousand, compared to approximately $673 in the prior-year period, representing year-over-year growth of approximately
7900%.
Total
operating expenses remained relatively consistent at approximately $3.56 million for the period ended March 31, 2026, compared to approximately
$3.57 million in the prior-year period, representing a slight decrease of approximately 0.2% year-over-year. Net loss was approximately
$3.4 million for the period ended March 31, 2026, compared to approximately $3.1 million in the prior-year period.
About
ArbliTM
ArbliTM
is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first
and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf
life at room temperature storage. ArbliTM is FDA-approved for the treatment of hypertension in patients greater than six years
old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy
in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, ArbliTM provides
a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, ArbliTM provides
consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan
prescriptions. ArbliTM has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
ArbliTM
is the first and only oral liquid formulation of losartan approved by the U.S. FDA. ArbliTM comes in a 165 mL bottle as a
peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date
of manufacture when stored at room temperature.
INDICATION
ArbliTM
is an angiotensin II receptor blocker (ARB) indicated for:
| |
● |
Treatment
of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk
of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. |
| |
|
|
| |
● |
Reduction
of the risk of stroke in patients with hypertension and left ventricular hypertrophy. |
| |
|
|
| |
● |
Treatment
of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. |
IMPORTANT
SAFETY INFORMATION
| |
● |
Do
not take ArbliTM when pregnant. When pregnancy is detected, discontinue ArbliTM as soon as possible. Drugs
that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ArbliTM can
cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and
third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. |
| |
|
|
| |
● |
Do
not co-administer ArbliTM with aliskiren in patients with diabetes. Avoid use of aliskiren with ArbliTM in
patients with renal impairment (GFR <60 mL/min). |
| |
|
|
| |
● |
Do
not administer ArbliTM in patients with severe hepatic impairment. ArbliTM has not been studied in patients
with severe hepatic impairment. |
| |
|
|
| |
● |
The
most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion,
and back pain. |
You
are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also contact Scienture at 1-833-754-4917.
Please
see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About
Hypertension
Hypertension
(high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According
to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million
people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher.
Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk
of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and
drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic
blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About
REZENOPYTM
REZENOPYTM
(naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose,
as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration
as emergency therapy in settings where opioids may be present.
REZENOPYTM
nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.
IMPORTANT
SAFETY INFORMATION
REZENOPYTM
(naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid
overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate
administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.
Important
Safety Information
| |
● |
Contraindications:
REZENOPYTM nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of
the other ingredients. |
| |
|
|
| |
● |
Warnings
and Precautions: |
| |
● |
Risk
of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under
continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance. |
| |
|
|
| |
● |
Risk
of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists
or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required. |
| |
|
|
| |
● |
Precipitation
of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal
may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal. |
| |
|
|
| |
● |
Risk
of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These
events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar
adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride. |
| |
● |
Adverse
Reactions: The following adverse reactions were observed in a REZENOPYTM nasal spray clinical study: upper abdominal pain,
nasopharyngitis, and dysgeusia. |
For
complete product information, including Patient Information, please refer to the full Prescribing Information.
About
Scienture Holdings, Inc.
SCIENTURE
HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company
focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market
needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals
who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare
systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and
channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary
Statements Regarding Forward-Looking Statements
This
press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities
laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking
statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,
our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management
team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the
success those products may have in the marketplace, such as ArbliTM and REZENOPYTM, and our strategies related
to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the
following words: “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,”
“project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words
does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties
(some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or
implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These
risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of
such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain
of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to
alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings
that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed
in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.
Forward-looking
statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided
by law.
Contact:
SCIENTURE
HOLDINGS, INC.
20
Austin Blvd
Commack,
NY 11725
Phone:
(866) 468-6535
Email:
IR@Scienture.com
Scienture
Holdings, Inc.
Condensed
Consolidated Balance Sheets
As
of March 31, 2026 and December 31, 2025
(Unaudited)
| | |
March 31, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| ASSETS | |
| | | |
| | |
| Current assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 3,542,754 | | |
$ | 6,662,008 | |
| Accounts receivable, net | |
| 722,545 | | |
| 731,328 | |
| Inventory | |
| 210,934 | | |
| 213,408 | |
| Prepaid expenses | |
| 250,427 | | |
| 262,278 | |
| Deferred offering costs | |
| 47,384 | | |
| 47,384 | |
| Total current assets | |
| 4,774,044 | | |
| 7,916,406 | |
| Property, plant and equipment, net | |
| 15,000 | | |
| 15,500 | |
| Notes receivable | |
| 5,000,000 | | |
| 5,000,000 | |
| Interest receivable | |
| 343,750 | | |
| 250,000 | |
| Intangible assets, net | |
| 70,519,218 | | |
| 70,973,064 | |
| Operating lease right-of-use assets | |
| 9,693 | | |
| 23,360 | |
| Total assets | |
$ | 80,661,705 | | |
$ | 84,178,330 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 1,404,794 | | |
$ | 1,443,266 | |
| Accrued liabilities | |
| 703,872 | | |
| 657,034 | |
| Operating lease liability - current | |
| 10,004 | | |
| 24,137 | |
| Warrant liability | |
| - | | |
| 10,914 | |
| Development agreement liability - current portion | |
| 685,000 | | |
| 600,000 | |
| Total current liabilities | |
| 2,803,670 | | |
| 2,735,351 | |
| Development agreement liability | |
| - | | |
| 285,000 | |
| Deferred tax liability | |
| 11,037,595 | | |
| 11,037,595 | |
| Total liabilities | |
| 13,841,265 | | |
| 14,057,946 | |
| | |
| | | |
| | |
| Commitments and contingencies (Note 15) | |
| | | |
| | |
| | |
| | | |
| | |
| Stockholders’ equity: | |
| | | |
| | |
| Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued | |
| | | |
| | |
| and outstanding as of both March 31, 2026 and December 31, 2025 | |
| - | | |
| - | |
| Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued | |
| | | |
| | |
| and outstanding as of both March 31, 2026 and December 31, 2025 | |
| - | | |
| - | |
| Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and | |
| | | |
| | |
| outstanding as of both March 31, 2026 and December 31, 2025 | |
| - | | |
| - | |
| Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and | |
| | | |
| | |
| outstanding as of both March 31, 2026 and December 31, 2025 | |
| - | | |
| - | |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 40,630,815 and 40,630,815 | |
| | | |
| | |
| shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | |
| | | |
| | |
| 1,015,000 and 1,015,000 shares unvested as of March 31, 2026 and December 31, 2025, | |
| | | |
| | |
| respectively | |
| 406 | | |
| 406 | |
| Additional paid-in capital | |
| 150,773,535 | | |
| 150,671,215 | |
| Accumulated deficit | |
| (83,953,501 | ) | |
| (80,551,237 | ) |
| Total stockholders’ equity | |
| 66,820,440 | | |
| 70,120,384 | |
| Total liabilities and stockholders’ equity | |
$ | 80,661,705 | | |
$ | 84,178,330 | |
Scienture
Holdings, Inc.
Condensed
Consolidated Statements of Operations
For
the Three Months Ended March 31, 2026 and 2025
(Unaudited)
| | |
Three Months Ended | |
| | |
March 31, | |
| | |
2026 | | |
2025 | |
| Revenues | |
$ | 56,325 | | |
$ | 10,258 | |
| Cost of sales | |
| 2,475 | | |
| 9,585 | |
| Gross profit | |
| 53,850 | | |
| 673 | |
| | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | |
| Wage and salary expense | |
| 420,008 | | |
| 696,068 | |
| Professional fees | |
| 932,552 | | |
| 412,850 | |
| Accounting and legal expense | |
| 326,178 | | |
| 470,825 | |
| Technology expense | |
| 15,763 | | |
| 61,620 | |
| General and administrative | |
| 1,074,864 | | |
| 1,355,948 | |
| Research and development | |
| 793,984 | | |
| 574,679 | |
| Total operating expenses | |
| 3,563,349 | | |
| 3,571,990 | |
| Operating loss | |
| (3,509,499 | ) | |
| (3,571,317 | ) |
| | |
| | | |
| | |
| Non-operating income (expense): | |
| | | |
| | |
| Change in fair value of warrant liability | |
| 10,910 | | |
| 645,986 | |
| Change in fair value of derivative liability | |
| - | | |
| 603,322 | |
| Loss on conversion of note payable | |
| - | | |
| (96,646 | ) |
| Interest income | |
| 133,344 | | |
| 25,442 | |
| Interest expense | |
| (37,019 | ) | |
| (670,784 | ) |
| Total non-operating expense | |
| 107,235 | | |
| 507,320 | |
| | |
| | | |
| | |
| Benefit (provision) for income taxes | |
| - | | |
| - | |
| Net loss | |
$ | (3,402,264 | ) | |
$ | (3,063,997 | ) |
| | |
| | | |
| | |
| Net loss per common share | |
| | | |
| | |
| Basic | |
$ | (0.08 | ) | |
$ | (0.33 | ) |
| Diluted | |
$ | (0.08 | ) | |
$ | (0.33 | ) |
| Weighted average common shares outstanding | |
| | | |
| | |
| Basic | |
| 40,630,815 | | |
| 9,425,751 | |
| Diluted | |
| 40,630,815 | | |
| 9,425,751 | |
